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This study was carried out to determine the effects of hepatitis B virus genotypes, core promoter mutations 
(A1762G1764→T1762A1764) as well as precore stop codon mutations (TGG→TAG) on HBeAg expression and HBeAg/ anti-
HBe status. Study was also performed on the effects of codon 15 variants (C1858/ T1858) on the predisposition of precore 
stop codon mutations (TGG→TAG). A total of 77 sera samples were analyzed. Fifty one samples were successfully 
genotyped of which the predominant genotype was genotype B (29/ 51, 56.9 %), followed by genotype C (16/ 51, 31.4 
%). Co-infections by genotypes B and C were observed in four samples (7.8 %). To a lesser degree, genotypes D and E 
(2.0 % each) were also observed. For core promoter mutations, the prevalence was 68.8 % (53/ 77) for A1762G1764 wild-
type and 14.3 % (11/ 77) for T1762A1764 mutant while 9.1 % (7/ 77) was co-infected by both strains. The prevalence of 
codon 15 variants was found to be 42.9 % (33/ 77) for T1858 variant and 16.9 % (13/ 77) for C1858 variant. No TAG 
mutation was found. In our study, no associations were found between genotypes (B and C) and core promoter 
mutations as well as codon 15 variants. Also  no correlation was observed between HBeAg/ anti-HBe status with 
genotypes (B and C) and core promoter mutations.    
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1.  Introduction 
The hepatitis B virus (HBV) is currently categorized 
into eight genotypes (A to H). The HBV genotyping 
system was first introduced by Okamoto et al. [23] with 
four genotypic groups (A to D) distinguished by 8.0 % 
threshold divergence between the genomes of HBV. 
Subsequently, the genotypes were extended to include 
genotypes E, F, G and H [3, 21, 29]. Thus, currently there 
are 8 accepted genotypes (A to H) for HBV. 
Genotypes have been found to be geographically 
distributed. Genotype A is predominant in Northern 
Europe and North America. Genotypes B and C are 
observed mainly in Asia including China, Japan and 
South-east Asian regions. The Mediterranean region has 
genotype D as the most prevalent strain. Genotype E is 
localized mainly in parts of East, Central and West Africa. 
As for genotype F, it is found mainly in South and Central 
Americas [21]. So far, genotype G has been found in the 
USA and France [29]. Genotype H is found in Central 
America [3].   
The presence of Hepatitis B e antigen (HBeAg) in the 
serum is used as a serological marker that correlates with 
the presence of viral replication with liver damage 
occurring. As HBeAg disappears from the serum, 
antibody to HBeAg (anti-HBe) will become detectable. 
The appearance of anti-HBe in the blood stream indicates 
biochemical and histological improvement of the liver 
injury with decreased viral detection. However, as anti-
HBe becomes prominent, the wild-type viral population 
will be replaced by mutants that do not produce or have 
decreased HBeAg expression. These mutants may be 
advantageously selected for by the anti-viral activity of 
the anti-HBe. The fact that HBV genome has a very high 
mutation rate which is estimated to be 104 fold higher than 
the human genome or at an estimated range of 1-10 x 10-5 
per site per year may also support the occurrence of the 
mutants [24, 27].   
A few mutations in the HBV genome could affect 
HBeAg production. The two which are widely studied are 
the core promoter dual mutations (A1762G1764→T1762A1764) 
and precore stop codon mutations (TGG→TAG). The core 
promoter mutations are located within the DNA 
regulatory element that binds to nuclear binding protein 
[32]. This region is located upstream of the transcriptional 
start sites for precore-mRNA and the pregenomic RNA 
(pgRNA) [37]. The transcript of 3.5 kb precore-mRNA is 
responsible for the translation of HBeAg while the 3.4 kb 
pgRNA transcript is used for viral core protein production 
and also serves as the template for viral DNA replication. 
These dual mutations could decrease the transcription of 
the precore-mRNA which is the precursor RNA template 
for the production of HBeAg but ironically increases the 
viral replicative capability as transcription of the pgRNA 
is enhanced [19]. Int. J. Med. Sci. 2006, 3 
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As for the precore stop codon mutation (TGG→TAG) 
at codon 28 of the precore/ core gene, it is a mutation that 
occurs in the nucleotide position of 1896, substituting 
guanine to adenine [4]. It is a nonsense mutation that 
converts tryptophan to a stop codon in the precore 
segment of the precore/ core gene. This will abort the 
translation of HBeAg. As HBeAg does not form part of the 
viral particle, it can be dispensed without affecting the 
formation of the viral particles.  
Although not involved in HBeAg production 
directly, codon 15 variants (C1858/ T1858) are significant as 
they are involved in base pair bonding with nucleotide 
1896 in the secondary loop structure of the pgRNA [33]. 
This loop structure functions as an encapsidation signal 
which recruits the HBV polymerase for the synthesis of 
HBV genome. The occurrence of cytosine at nucleotide 
1858 (C1858 variant) prevents the stable formation of 
precore stop codon mutation (TGG→TAG) due to the 
weak binding force with adenine at nucleotide 1896, thus 
destabilizing the secondary loop structure. Whereas 
thymine at nucleotide 1858 (T1858 variant) allows flexibility 
in that it can stably bonds with adenine at nucleotide 1896 
and so resulting in precore stop codon mutation 
(TGG→TAG) but can also wobble pairs with guanine at 
nucleotide 1896 in the TGG wild-type without disrupting 
the secondary loop structure [17].     
A number of reports have been published on the 
correlations between HBV genotypes, core promoter 
mutations (A1762G1764→T1762A1764), precore stop codon 
mutations (TGG→TAG), codon 15 variants (C1858/ T1858) 
and HBeAg/ anti-HBe status but conflicting results have 
been observed. Therefore, it is our interest to examine 
these correlations in HBV originated from Malaysian 
carriers.  
2.  Materials and Methods 
Samples 
A total of 77 sera samples infected with HBV were 
used in this study. Samples were collected from the 
Tengku Ampuan Rahimah Hospital, Klang, Malaysia, 
Sunway Medical Center, Malaysia and Hospital Universiti 
Kebangsaan, Malaysia. The HBV carriers were diagnosed 
through routine blood screening for hepatitis B surface 
antigen (HBsAg) and were tested positive for HBsAg for 
more than 6 months of repeated testing. Sera samples 
were withdrawn from infected individuals using sterile 
syringes and were stored in individual blood collection 
tubes to avoid cross-contamination. These were kept at -70 
oC until required. Patients’ consents were obtained prior 
to study. 
Preparation prior to PCR 
Samples were concentrated using Integrated 
SpeedVac™  System (ISS-110) (Savant Technologies) at 
medium drying rate for 2 hours. Approximately 1.4 mL 
serum was concentrated to a final volume of 400 μL. The 
concentrated sera were then centrifuged for 10 minutes at 
20000 g to separate any lipid or protein found in 
suspension. Subsequently, HBV nucleic acids were 
extracted from 200 μL of the concentrated sera using High 
Pure Viral Nucleic Acid Kit (Roche).  
Genotyping using nested PCR with type specific primers 
PCR amplifications were performed using PCR 
Reagent System (Invitrogen). Two sets of primers 
developed by Naito et al. [20] were used. The first set 
amplified the region between pre-S and S regions of HBV 
genome. The amplified PCR product was then subjected 
to another round of PCR using the second set of primers 
consisting of 6 pairs of primers. Each primer pair would 
yield PCR product with size that corresponds to a 
genotype (A to F).  
Genotyping using PCR-RFLP on the pre-S region 
This method was performed to complement the 
genotyping method above in order to obtain an overall 
better result on the genotypes of the HBV. Primers 
designed by Lindh et al. [14] were used to amplify the pre-
S region of the HBV genome using PCR Reagent System 
(Invitrogen). PCR products were digested separately with 
AvaII (New England Biolabs) and DpnII (New England 
Biolabs) to produce restriction fragment length 
polymorphism (RFLP) patterns. These patterns were 
compared with patterns of known genotypes (A to F) as 
observed by Lindh et al. [14].  
Core promoter mutations (A
1762G
1764→T
1762A
1764) 
analysis 
The method for this analysis was adapted from 
Takahashi et al. [32]. This method was based on the 
creation of Sau3AI restriction site on the PCR product if 
T1762A1764 dual mutations were present. The PCR product 
amplified from A1762G1764 wild-type would not have the 
restriction site created. Subsequently, PCR products were 
digested with Sau3AI (New England Biolabs) and 
observed on 2.0 % agarose gel (Promega). Digested 
products for T1762A1764 dual mutations would yield 197 bp 
and 110 bp while A1762G1764 wild-type would be 
undigested and remained at 307 bp.  
Codon 15 variants (C
1858/ T
1858) analysis 
The method used for this analysis was adapted from 
Lindh et al. [16]. Using primers designed by Lindh et al. 
[16],  EcoNI restriction site would be created when PCR 
amplification on T1858 variant was performed. 
Amplification with C1858 variant as the template would not 
produce the restriction site.  Subsequently, PCR products 
were digested with EcoNI (New England Biolabs) and 
observed on 2.0 % agarose gel (Promega). T1858 variant 
would produce 20 bp and 190 bp restriction products 
while C1858 variant would be undigested and remained at 
210 bp.  
Precore stop codon mutations (TGG→TAG) analysis 
The method for this analysis was adapted from 
Lindh et al. [13]. This method was based on creation of 
Bsu36I restriction site on the PCR product if precore stop 
codon mutation (TAG) was present. The PCR product 
amplified from wild-type without the precore mutation 
(TGG) would not have the restriction site. Subsequently, 
PCR products were digested with Bsu36I (New England 
Biolabs) and observed on 2.0 % agarose gel (Promega). 
Digested DNA products for precore stop codon mutants 
(TAG) would yield 34 bp and 160 bp while DNA from 
precore wild-type (TGG) would be undigested and remain 
at 194 bp.  
HBeAg/ anti-HBe status determination 
The determinations of the HBeAg and anti-HBe 
status were performed on unconcentrated sera using 
AxSYM® HBe 2.0 (Abbott) and AxSYM® anti-HBe 
(Abbott) immunoassay kits in the Abbott AxSYM® 
System (Abbott) automated blood analyzer. Int. J. Med. Sci. 2006, 3 
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Quantifications for relative titer levels of both HBeAg and 
anti-HBe were performed based on the mean rate of the 
Index Calibrator provided and calculated as the cutoff 
rate, CO. The calculation was based on the ratio of the 
sample signal rate to cutoff rate for each of sample and 
control (S/CO). A sample was considered to be HBeAg 
positive when its S/CO ratio was ≥ 1.0 and anti-HBe 
positive when its S/CO ratio was < 1.0. In the case for 
anti-HBe, a smaller S/CO ratio registered indicated a 
higher level of the antibody. To better reflect the anti-HBe 
relative titers, unit for anti-HBe was reported as CO/ S in 
this paper.     
Statistical analysis 
Chi-square tests were performed between the 
genotypes, core promoter mutations, codon 15 variants, 
precore stop codon mutations and HBeAg/ anti-HBe 
status. Kruskal-Wallis non-parametric ranked sum test 
was used to analyze the correlation between the 
genotypes and core promoter mutations with the relative 
mean HBeAg titer levels. A P value of less than or equal to 
0.050 was considered to be significant.    
3.  Results 
HBV genotypes observed using nested PCR with type 
specific primers 
Using this method, 37.7 % (29/ 77) of the samples 
were found to be infected by HBV genotype B, 19.5 % (15/ 
77) by genotype C, 1.3 % (1/ 77) by genotype D, 1.3 % (1/ 
77) by genotype E and 3.9 % (3/ 77) by co-infections of 
genotypes B and C whereas 36.4 % (28/ 77) did not yield 
any PCR products (Table 1). 
HBV genotypes observed using PCR-RFLP on the pre-S 
region 
Using this method, 13.0 % (10/ 77) of the samples 
were found to be infected by HBV genotype B, 6.5 % (5/ 
77) by genotype C, 1.3 % (1/ 77) by co-infections of 
genotypes B and C (Table 1). Nine sera (11.7 %) yielded 
low HBV-DNA PCR products where genotypes could not 
be determined while three sera (3.9 %) produced unique 
RFLP patterns that did not correspond to any RFLP 
patterns with known genotypes as observed by Lindh et 
al. [14]. 63.6 % (49/ 77) of the samples did not yield any 
HBV-DNA PCR products.    
Table 1: The genotypes determined by the two different 
methods 
Genotypes Determined by the different methods used  Metho
ds 
used 
B  C  D  E  B and C 
co-
infectio
ns 
Low 
PCR 
product
s* 
Untypabl
e+ 
PCR 
negati
ve 
Tot
al 
Naito 
et al. 
(2001) 
29 
(37.7
%) 
15 
(19.5
%) 
1 
(1.3
%) 
1 
(1.3
%) 
3 
(3.9%) 
−  − 28 
(36.4%
) 
 
77 
Lindh 
et al. 
(1998) 
10 
(13.0
%) 
5 
(6.5%
) 
−  − 1 
(1.3%) 
9 
(11.7%) 
3 
(3.9%) 
49 
(63.6%
) 
77 
* PCR product yield low thus genotype could not be determined accurately. 
+ Genotype untypable due to unique RFLP pattern produced that did not 
correspond to any known genotyped RFLP pattern as observed by Lindh et al. 
[14]. 
Overall genotypes observed using the two genotyping 
methods above 
Combining the results from both genotyping 
methods, the prevalence were 56.9 % (29/ 51) for 
genotype B, 341.4 % (16/ 51) for genotype C, 2.0 % (1/ 51) 
each for genotypes D and E respectively (Table 2). Four of 
the sera (7.8 %) were co-infected by genotypes B and C. 
Table 2: Combination of genotyping results determined using 
methods developed by Lindh et al. [14] and Naito et al. [20] 
Genotypes   
B  C  D  E  B and C* Total 
Number of samples  29 
(56.9%) 
16 
(31.4%) 
1 
(2.0%) 
1 
(2.0%) 
4 
(7.8%) 
51 
* Genotypes B and C co-infections. This included a sample that was determined 
to be genotype C when using method developed by Naito et al. [20] but was 
determined to be co-infected by genotypes B and C when method developed by 
Lindh et al. [14] was used.  
Core promoter mutations (A
1762G
1764→T
1762A
1764) 
Of the 77 sera analyzed, it was observed that 53 sera 
(68.8 %) were infected by A1762G1764 wild-type virus while 
11 (14.3 %) by T1762A1764 mutants. Seven (9.1 %) of the sera 
were found to be co-infected by both A1762G1764 wild-type 
and T1762A1764  mutant. Six sera did not yield any PCR 
product. Statistical analysis between the genotypes B and 
C with A1762G1764 wild-type, T1762A1764  mutants and co-
infections by A1762G1764 wild-type and T1762A1764  mutants 
gave a P value of 0.054 which was very closed to being 
significant (Table 3). 
Table 3: Distribution of genotypes B and C with core promoter 
mutations and codon 15 variants  
Core promoter mutations  Codon 15 
variants 
Genotypes 
A1762G1764 wild-
type 
T1762A1764 
mutant 
Co-
infections 
T1858 C 1858 
B 20 
(71.4 %) 
2 
(7.1 %) 
6 
(21.4 %) 
16 
(84.2 
%) 
3 
(15.8 
%) 
C 12 
(75.0 %) 
4 
(25.0 %) 
− 8 
(72.7 
%) 
3 
(27.3 
%) 
Note: samples that were co-infected by genotypes B and C were not included. 
Codon 15 variants (C
1858/ T
1858) 
Of the 77 sera, 46 of them yielded PCR products and 
were analyzed for the codon 15 variants. The prevalence 
of codon 15 variants was found to be 42.9 % (33/ 77) for 
T1858  variant and 16.9 % (13/ 77) for C1858 variant. No 
correlation was found between genotypes B and C with 
C1858/ T1858 variants (P= 0.45) (Table 3).  
Precore stop codon mutations (TGG→TAG) 
71 (92.2 %) of the sera yielded PCR products with all 
being TGG wild-type. The rest did not yield any PCR 
products.  
HBeAg/ anti-HBe status 
It was observed that 42.9 % (33/ 77) of the sera were 
HBeAg positive while 54.5 % (42/ 77) of the sera were 
anti-HBe positive. Two sera (2.6 %) were found to be 
positive for both HBeAg and anti-HBe. Chi-square test 
between genotypes B and C with HBeAg/ anti-HBe status 
revealed no significant difference (P= 0.34) (Table 4). This 
was also true for core promoter mutations (A1762G1764 
wild-type, T1762A1764 mutants and co-infections) with the 
HBeAg/ anti-HBe status (P= 0.77) (Table 5).  Int. J. Med. Sci. 2006, 3 
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Table 4: Distribution of genotypes B and C with HBe/ anti-HBe 
status 
Genotypes  HBe Anti-HBe 
B 15 
(51.7 %) 
14 
(48.3 %) 
C 10 
(66.7 %) 
5 
(33.3 %) 
Note: samples that were co-infected with genotypes B and C were not included. 
This also applied to samples with positivity for both HBe and anti-HBe. 
Table 5: Distribution of core promoter mutations with HBe/ 
anti-HBe status 
HBe   Anti-HBe  Core promoter mutations 
n S/  CO*  n 
A1762G1764 wild-type  23 
(43.4 %) 
217.0 ± 123.7  30 
(56.6 %) 
T1762A1764 mutant 5 
(45.5 %) 
108.1 ± 100.2  6 
(54.5 %) 
Co-infections 4 
(57.1 %) 
187.7 ± 124.7  3 
(42.9 %) 
* Reported as mean ± standard deviation. 
HBeAg/ anti-HBe relative titer levels 
The relative mean titer for HBeAg was 195.9 S/ CO 
with standard deviation of 123.5. Categorically, for core 
promoter mutations status, A1762G1764 wild-type, T1762A1764 
mutants and co-infections had relative mean titer levels of 
217.0 ± 123.7 S/ CO, 108.1 ± 100.2 S/ CO and 184.7 ± 124.7 
S/ CO respectively (Table 5). However, a Kruskal-Wallis 
test between the HBeAg relative titer levels of the core 
promoter mutations status did not reveal any significant 
difference (P= 0.27). No comparison could be made for 
precore stop codon mutations as no TAG was detected in 
this study. The relative mean titer observed for anti-HBe 
was 12.7 CO/ S with standard deviation of 14.7 CO/ S. 
The high standard deviation seen was due to a single 
outlier with very high relative titer of 100.0 CO/ S when 
compared with others.  
4.  Discussion 
From the comparisons of the observations of HBV 
genotypes using the two above methods, it could be 
deduced that the genotyping method using nested PCR 
with type specific primers was more sensitive than PCR-
RFLP on the pre-S region. There was overall consistency 
between the genotypes observed using nested PCR with 
type specific primers with PCR-RFLP on the pre-S region. 
No different genotype was observed for any one 
particular sample except for the cases involving co-
infections by genotypes B and C. The genotypes B and C 
co-infection observed using PCR-RFLP on the pre-S region 
was found to be infected only by genotype C when nested 
PCR with type specific primers was used. Comparison 
could not be made for the genotypes B and C co-infections 
observed using nested PCR with type specific primers as 
no PCR product was obtained for these particular samples 
when PCR-RFLP on the pre-S region was used. We 
attempted to verify two of the three co-infections 
produced by the nested PCR technique through cloning 
and sequencing but we only managed to obtain singular 
genotypic infections for every each of them (data not 
shown). The single co-infection sample produced by the 
PCR-RFLP technique was checked using cloning and 
restriction analysis with AvaII and DpnII. However, we 
only managed to verify for the presence of genotype C 
infection in all the clones screened (data not shown). The 
reason for these observations could be attributed to the 
small clone numbers we had used for sequencing and the 
single genotypes observed might be the predominant 
species. The three un-typed RFLP patterns observed using 
PCR-RFLP on the pre-S region were determined to be of 
one genotype B and two genotypes C respectively when 
the nested PCR with type specific primers was used. 
These were verified through sequencing of the PCR 
products produced by the PCR-RFLP technique (data not 
shown). The low PCR product yields obtained using the 
PCR-RFLP on the pre-S region could be due to the nature 
of the technique used where amplification was performed 
only once. This was in contrast to the nested PCR 
technique where two rounds of amplifications were 
performed. In the subsequent statistical tests, co-infections 
by genotypes B and C as well as genotypes D and E were 
excluded from analyses.  
Our observation for the prevalence of genotypes was 
in concordance with those results reported by a few 
studies [11, 14, 23]. The studies showed that genotypes B 
and C were more common in the Asia-Pacific regions with 
genotype B being more predominant. We had indeed 
observed that genotypes B and C were the main strains 
infecting HBV carriers in Malaysia with the former being 
more predominant. However region-wise, this result was 
different from that reported by Sugauchi et al. [30] who 
reported that genotype C was more predominant in the 
Thai population. In Japan, genotype C was more 
predominant than genotype B [24]. All these observations 
followed the trend that genotypes B and C were localized 
in the Asia-Pacific regions but with varying degree of 
predominance. Given the same geographic endemicity of 
genotypes B and C, co-infections by these two genotypes 
are not surprising. Few other studies had also reported 
genotypic co-infections [10, 35]. This shows that co-
infections could be quite common indeed. 
Many studies had shown that the core promoter 
mutations (A1762G1764→T1762A1764) were more common in 
genotype C than in genotype B [9, 15, 25, 28]. The present 
study did not detect significant difference. Nevertheless, it 
is interesting to note that the statistical test produced a 
result which was very close to being significant (P= 0.054). 
Possibly, a significant result could be obtained given a 
bigger sample size. In some other studies, correlation 
between genotypes and core promoter mutations was not 
observed [7, 11]. The conflicting results observed could 
imply that there might be other factors that are involved 
in determining the correlation.  
S u g a u c h i  e t  a l .  [ 3 1 ]  h a d  p r o p o s e d  t h a t  w i t h i n  
genotype B, two genotype B subtypes exist namely Bj 
which is found mainly in Japan and Ba which is found in 
some other Asian countries such as China, Hong Kong, 
Taiwan, Thailand and Vietnam. The Ba strain has 
recombination with genotype C in the precore region and 
the core gene whereas Bj strain is without any 
recombination [31]. They observed that Ba strain had 
higher prevalence of the core promoter mutations than in 
Bj strain (33 % vs. 15 %). This fact might be relevant to our 
case as the subtypes might influence the observation we 
had. The observation by Sugauchi et al. [31] has made the 
subtypes Ba and Bj as another variable to look at in the 
correlation analysis between genotypes and core promoter 
mutations. The varying proportions of the Ba and Bj 
subtypes within genotype B samples might influence the 
correlation outcome of the core promoter mutations with Int. J. Med. Sci. 2006, 3 
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genotype B. As we do not know the proportions of Ba and 
Bj subtypes in our genotype B samples, thus the core 
promoter mutations we observed might be influenced by 
the varying degree of proportions of Ba and Bj subtypes. 
Besides that, the co-infections of both A1762G1764 wild-type 
and T1762A1764 mutants in our genotype B samples could be 
attributed by co-infections of Ba and Bj subtypes, where 
one subtype contributed the A1762G1764 wild-type and the 
other subtype contributed the core promoter mutation. It 
is interesting to note that only genotype B samples had co-
infections of both A1762G1764 wild-type and T1762A1764 
mutants but this phenomenon was not observed for 
genotype C samples.  
Several studies revealed that core promoter 
mutations might be influenced by the existence of precore 
stop codon mutations where an inverse relationship 
between core promoter mutations and precore stop codon 
mutations was seen [5, 6]. However, we observed 
otherwise, where low numbers of core promoter 
mutations were observed and no precore stop codon 
mutations were observed. Thus, it could be that core 
promoter mutations might also be influenced by factors 
such as geography or ethnicity, hence the prevalence of 
core promoter mutations were not based on genotypes 
alone. Although Malaysia has a multi-ethnic population 
(mainly inhabited by the Malays, Chinese and Indians in 
respective order of proportions), we were not able to 
perform the relationships with the ethnics due to 
incomplete data of the ethnic origins of our samples.  
Associations between codon 15 variants (C1858/ T1858) 
and genotypes had been mentioned. The C1858 variant was 
closely associated with genotypes A, F and H as well as 
genotype C but not with genotypes B, D and E [2, 3, 12]. In 
our case, although 15.8 % (3/ 19) of the genotype B with 
positive results for codon 15 analysis was C1858 variant, 
significant difference was not observed (P= 0.45). 
Nevertheless, we still observed a higher prevalence of 
C1858 variants in genotype C samples than in genotype B 
(27.3 % vs. 15.8%).  
In this study, analysis on codon 28 at the precore 
region revealed that all the sera were infected by TGG 
wild-type. A few studies had observed certain correlations 
between genotypes and precore stop codon mutations 
(TGG→ TAG )  [ 6 ,  7 ,  1 5 ] .  W i t h i n  t h e  s a m e  g e o g r a p h i c  
region, Huy et al. [9] reported that genotype B was linked 
to TAG mutation. However, conflicting results on the 
correlation between genotypes and precore stop codon 
mutations (TGG→ TAG) had been reported elsewhere. 
Orito et al. [25] observed no significant difference between 
the predispositions to TAG mutation development 
between genotypes B and C. Besides that, Kidd-Ljunggren 
et al. [11] did not observe any such correlation in samples 
of various geographic origins. As no TAG mutation was 
observed in our case, this study was in contrast to that of 
Huy et al. [9] where in our case, TAG mutation was 
predisposed by genotype B even though large number of 
genotype B samples was observed (n= 28). The failure to 
observe any TAG mutation in our case might be 
significant by itself. This is because various other studies 
reported at least some precore stop codon mutations in 
their study [6, 7, 9, 11, 15, 25]. Thus, it could be possible 
that TAG mutations are influenced by other factors as well 
such as geography, ages and ethnics. Besides that, 
genotype B subtypes might play a role here. Although no 
significant difference was observed, Sugauchi et al. [31] 
reported that TAG mutations were more frequent in Bj 
than Ba subtype (50% vs. 18 %). Therefore, there is a 
possibility that there is a higher prevalence of Ba subtype 
in our samples which leads to the absence of any TAG 
mutants. However, many other Asian countries such as 
China, Thailand and Vietnam where high prevalence of 
Ba was reported, still observed the occurrences of TAG 
mutants [31].   
Based on the secondary stem loop structure of the 
pgRNA, theoretically, there should be correlation between 
nucleotide at 1858 in codon 15 with nucleotide at 1896 in 
precore region at codon 28 of the precore/ core gene [33]. 
No correlation analysis could be made in our study as no 
TAG mutation was observed. Nevertheless, our result 
fitted the general concept in that no TAG mutation should 
occur together with C1858 variant as we did not observe the 
co-existence of C1858 variants with TAG mutations.  
No significant correlation was observed between 
HBeAg/ anti-HBe status with genotypes B and C. This is 
in contrast to several studies which reported that patients 
infected by HBV genotype B were more prone to be 
HBeAg negativity than those infected by genotype C [15, 
28]. On a regional basis, this study was also in contrast to 
that reported by Sugauchi et al. [30] where in a Thai 
population, they observed that HBeAg positivity were 
more prevalent in sera infected by genotype C than by 
genotype B. Some studies had shown that patients 
infected by genotype C experienced longer period of 
being in HBeAg positivity with delayed seroconversion to 
anti-HBe status [15, 24]. This might explain the reason 
why correlation was not observed in this study. If the 
above statement held true, the proportion of HBeAg/ 
anti-HBe could depend on the timing of sample collection 
as well. This could complicate the matter in hands as one 
would seldom know when infection was initiated.   
The emergence of anti-HBe immunity puts selective 
pressure against the HBV that express HBeAg. 
Hepatocytes harbouring the wild-type HBV would be 
eliminated due to the display of HBeAg on the cell 
membrane which would be targeted by the immune 
response. Thus mutants that lack or have decreased 
HBeAg expression would evade the immune response 
and survive [26]. The observation of co-infections by both 
A1762G1764 wild-type and T1762A1764 mutants could indicate 
an ongoing selection process, which given time, could see 
the total exclusion of the wild-type. Regrettably, we were 
not able to follow up on the cases studied for a longer 
period of time. As the HBV were under selective pressure, 
they might evolve fully into mutants sometime in the 
future. 
Statistical significant difference was not observed for 
HBeAg/ anti-HBe status with core promoter mutations 
(A1762G1764→T1762A1764) .  T h i s  w a s  i n  c o n t r a s t  t o  s o m e  
observations reported where core promoter mutations 
(A1762G1764→T1762A1764) were linked to HBeAg 
seroconversion to anti-HBe [8, 22]. In concordance to this 
study, a few reports did not find any correlation between 
the core promoter mutations with HBeAg/ anti-HBe 
status [7, 15, 25, 32]. We observed a substantial number of 
T1762A1764  mutants infecting sera with HBeAg positivity. 
This phenomenon could be explained by the fact that the 
occurrence of T1762A1764  mutation only decreased the 
production of HBeAg, not totally abolishing it. Therefore, 
the presence of T1762A1764  mutants does not necessarily 
mean the absence of HBeAg detection. Many other reports Int. J. Med. Sci. 2006, 3 
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also observed the occurrences of T1762A1764  mutants in 
HBeAg positive sera [5, 7, 8, 22, 32]. Analysis between 
core promoter mutations with relative mean titer levels 
did not show any significant correlation. Possible reason 
for this was that HBeAg expression reduction made by 
T1762A1764 mutation alone was quite low (by about 20 %) 
and was not enough to decrease the HBeAg level to a 
point where statistical significance was observed [26]. This 
could explain the observation for one sample where a 
relatively high HBeAg titer (273.8 S/ CO) could be 
observed in the presence of T1762A1764 mutation. It could be 
that the HBeAg expression by the virus was only reduced 
minimally. Besides that, T1762A1764 mutants could become 
predominant even before the emergence of anti-HBe 
especially during the late HBeAg positive phase [5, 26]. 
Other samples infected by T1762A1764  mutants had 
considerably lower HBeAg titer levels which could be 
attributed to mutations occurring elsewhere. Parekh et al. 
[26] showed that mutations at nucleotides 1753 and 1766 
in addition to the T1762A1764  mutation could decrease 
HBeAg expression by up to 80 %. Mutations downstream 
of the precore start codon could also decrease HBeAg 
translation [1]. We also detected anti-HBe in sera infected 
by HBV without mutations at both the core promoter and 
precore stop codon mutations. There were possibilities 
that other mutations occurred that abolish the HBeAg 
production such as mutation at the precore start codon or 
TAA stop mutation at codon 2 [16]. This could be the case 
for one sample which recorded a relatively very high anti-
HBe level (100.0 CO/ S) but still being a wild-type. For 
other cases, it could also be that enough wild-type viruses 
survived the weak onslaught of the immune system and 
be detected in the study. Our result showed that the 
average relative anti-HBe titer was quite low but we must 
admit that there was no benchmark that could be taken as 
norm. However, the observation that a relative titer of 
100.0 CO/ S detected in this study indicated that anti-HBe 
could reach quite high a level indeed. 
Although we observed that 54.5 % (42/ 77) of our 
samples were HBeAg negative, we were not able to 
perform a more detailed analysis on the HBeAg-negative 
chronic patients. This was because we had difficulty in 
discerning between HBeAg-negative chronic patients with 
inactive HBsAg carriers, especially when most of our 
samples consisted of blood donors. The criteria for being a  
HBeAg-negative chronic is that a patient has recurrence of 
HBsAg for more than 6 months, negative for HBeAg, 
positive for anti-HBe, HBV DNA presence of more than 
105 to 106 copies/ mL, increased alanine aminotransferase 
(ALT) level with histological liver injury. For being an 
inactive HBsAg carrier, the patient is negative for HBeAg, 
positive for anti-HBe, has undetectable or low HBV DNA 
level, repeatedly normal ALT with none or minimal 
histological liver injury [18]. With these criteria in hand, 
we could not categorize the samples accordingly due to 
incomplete data on the HBV DNA levels, ALT levels and 
histological liver injuries. Many blood donors were 
unaware that they were infected with HBV until they 
were found positive for HBsAg during routine screening. 
Some blood donors might have HBeAg-negative chronic 
hepatitis B infections without knowing it.  
Another study was carried out by us on HBV DNA 
levels in 66 sera samples using real-time PCR (data not 
shown). Conflicting results had been reported on the 
correlations between the genotypes with HBV DNA levels 
[30, 36]. We found that genotypes B and C were not 
significantly associated with HBV DNA levels but 
individuals infected with genotype C were inclined 
towards greater than 106 copies/ mL (high viral load). 
Besides that, it has been suggested that the core promoter 
mutations might favour more efficient viral replication 
which may imply a higher HBV DNA level [15, 19]. 
However, we observed that the core promoter mutations 
were not significantly linked to HBV DNA levels which 
were in concordance to several reports [25, 34]. 
Interestingly, samples co-infected by both A1762G1764 wild-
type and T1762A1764 mutants had higher HBV DNA levels. 
However, one must treat this result cautiously as the 
phase of HBV infection at which the sera samples were 
obtained would affect the HBV DNA level concentrations.  
In conclusion, the predominant HBV genotypes in 
the Malaysian carriers was genotype B followed by 
genotype C. No significant correlations were observed 
between HBV genotypes, core promoter mutations 
(A1762G1764→T1762A1764) and HBeAg/ anti-HBe status. 
Conflicting results regarding the correlations had been 
reported. The correlations of these variables could be 
influenced by other various factors which had thus made 
any concrete correlation to be elusive so far. One possible 
major influence could be due to the genotype B subtypes 
Ba and Bj. Hence, it would be interesting to do further 
research along this path.  
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